# SWOG S0221 adjuvant chemotherapy schedules

Source: https://onco.cc/trials/nct00070564/  
OnCo record `nct00070564` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

S0221 compares schedules for chemotherapy after breast surgery. It studies which schedule controls cancer while tracking side effects.

## Summary

S0221 compares schedules for chemotherapy after breast surgery. It studies which schedule controls cancer while tracking side effects.

Interventional study registered as NCT00070564, sponsored by SWOG Cancer Research Network. Registry phase: 3. Registry enrollment is 3,294 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-10
- Also known as: S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT00070564
- Phase: 3
- Setting: Resected stage I to III breast cancer
- Sponsor: SWOG Cancer Research Network
- Enrolled: 3294

## Sources

- ClinicalTrials.gov NCT00070564: https://clinicaltrials.gov/study/NCT00070564
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT00070564

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct00070564.json